-

11:19:20 PM

MYNZ Stock News

MYNZ - Mainz Biomed B.V.

01/19/22 3:01 AM

Nasdaq : MYNZ

clinical trial

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

Mainz Biomed N.V.

RHEA-AI

very positive

01/12/22 3:01 AM

Nasdaq : MYNZ

management

Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its

RHEA-AI

neutral

01/11/22 3:01 AM

Nasdaq : MYNZ

conferences

Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will

RHEA-AI

neutral

01/05/22 3:01 AM

Nasdaq : MYNZ

acquisition

Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022

RHEA-AI

very positive

12/21/21 3:01 AM

Nasdaq : MYNZ

managementfda approval

Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Karen Richards as its Vice President

RHEA-AI

very positive

12/14/21 3:01 AM

Nasdaq : MYNZ

Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe

Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany GANZIMMUN Diagnostics has an interdisciplinary team of over 370 medical technical assistants, physicians, chemists, biologists, and nutritionists who process approximately 5,500 laboratory

RHEA-AI

neutral

12/07/21 3:01 AM

Nasdaq : MYNZ

covid-19

Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of

RHEA-AI

neutral

11/30/21 3:01 AM

Nasdaq : MYNZ

partnership

Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announced today the Company has engaged Precision for Medicine, a

RHEA-AI

very positive

11/18/21 3:01 AM

Nasdaq : MYNZ

management

Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic

RHEA-AI

neutral

11/15/21 3:01 AM

Nasdaq : MYNZ

Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that Company representatives will be attending

RHEA-AI

neutral